A Phase 1, Open-Label, Randomized, Three-Period Crossover Drug Interaction Study Evaluating the Pharmacokinetic Profiles of SPD503 and VYVANSE, Administered Alone and in Combination in Healthy Adult Volunteers.

Trial Profile

A Phase 1, Open-Label, Randomized, Three-Period Crossover Drug Interaction Study Evaluating the Pharmacokinetic Profiles of SPD503 and VYVANSE, Administered Alone and in Combination in Healthy Adult Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Jun 2015

At a glance

  • Drugs Guanfacine (Primary) ; Lisdexamfetamine (Primary)
  • Indications Attention-deficit hyperactivity disorder; Bipolar disorders; Eating disorders; Generalised anxiety disorder; Social phobia
  • Focus Pharmacokinetics
  • Sponsors Shire
  • Most Recent Events

    • 19 Aug 2009 Status changed from active, no longer recruiting to completed as reported by CLinicalTrials.gov
    • 16 Jul 2009 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov
    • 17 Jun 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top